Monica Abrante, MD
Internal Medicine · Mesa, AZNPI 1295899359
Payments from drug & device makers
Across 163 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$614
- Novo Nordisk$537
- Boehringer Ingelheim$404
- Philips North America LLC$289
- Astellas Pharma US Inc$272
- Amgen$247
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,64297%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $614 |
| Novo Nordisk | 16 | $537 |
| Boehringer Ingelheim | 21 | $404 |
| Philips North America LLC | 16 | $289 |
| Astellas Pharma US Inc | 5 | $272 |
| Amgen | 9 | $247 |
| GSK | 14 | $236 |
| UCB, Inc. | 7 | $235 |
| Sanofi-aventis U.S. LLC | 16 | $200 |
| AbbVie(2 entities) | 7 | $113 |
| Grifols USA, LLC | 4 | $83 |
| Lilly USA, LLC | 3 | $82 |
| Johnson & Johnson | 4 | $60 |
| Novartis | 4 | $54 |
| Xeris Pharmaceuticals, Inc. | 3 | $44 |
| Abbott | 2 | $42 |
| Pfizer | 2 | $30 |
| Merck | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Boston Scientific | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Seqirus USA Inc | 1 | $12 |
| Zyla Life Sciences, Inc. | 1 | $11 |
| Cequr Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,742 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 177 | $202,763 |
| EliquisApixaban | 54 | $78,529 |
| OzempicSemaglutide | 39 | $47,112 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $33,540 |
| FarxigaDapagliflozin Propanediol | 26 | $30,884 |
| TrulicityDulaglutide | 13 | $30,756 |
| LinzessLinaclotide | 30 | $28,270 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $27,333 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $24,345 |
| RybelsusSemaglutide | 12 | $21,510 |
| JanuviaSitagliptin Phosphate | 11 | $18,760 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $17,509 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $14,395 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $11,857 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $11,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $404 | $211,367190 claims |
| PfizerEliquis | $30 | $78,52954 claims |
| Novo NordiskOzempic, Rybelsus | $537 | $68,62251 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $236 | $60,87367 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $614 | $42,74147 claims |
| MerckJanuvia, Janumet | $29 | $36,26929 claims |
| AbbVieLinzess, Synthroid | $113 | $30,76675 claims |
| Lilly USA, LLCTrulicity | $82 | $30,75613 claims |
| Astellas Pharma US IncMyrbetriq | $272 | $10,38811 claims |
| Sanofi-aventis U.S. LLCLantus | $200 | $5,08228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Mesa
- Yessica SachdevaMesa$13.7M
- Tami BruceMesa$976K
- Ali ImranMesa$240K
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.